Search

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
GET IN TOUCH
Brochure

Integrated DMPK services for lead optimization and IND filing

Download PDF
Integrated DMPK services for lead optimization and IND filing.
Aragen’s uniqueness comes from its ability to provide comprehensive DMPK expertise and technologies from the early drug discovery to lead optimization processes, and IND filing for small and large molecules. We help our customers with different mechanistic DMPK studies including in vitro ADME and in vivo PK as a part of the whole process to rank compounds, optimize their properties and to be developed from the typical efficacious hits to drug like candidates.
TIER 1 ASSAYS
  • Solubility (Kinetic and Thermodynamic, SIF, SGF)
  • Log P and Log D
  • PAMPA (GIT, BBB and Skin)
  • Metabolic stability in microsomes and hepatocytes (2 time points, Multispecies)
  • Protein binding (Single concentration)
  • Cocktail CYP inhibition, HLM (Single concentration, 5 CYPs)
  • Cassette IV PK
  • Cassette PO PK
TIER 2 ASSAYS
  • Plasma protein binding (3 concentrations, 3-5 species)
  • Metabolic stability (Intrinsic Clearance)
  • Plasma/blood stability
  • CYP Inhibition (IC50, Ki)
  • Met ID (soft spot), species comparison
  • Blood / plasma Partitioning
  • Time dependent inhibition / Mechanism based inactivation
  • Reactive metabolites
  • MDCK and Caco-2 permeability
  • Rat IV PO PK
  • Mouse IV PO PK
  • Dog IV PO PK
  • Blood brain barrier penetration studies (Brain and CSF)
    in rodents
TIER 3 ASSAY
  • Reaction Phenotyping
  • Single raising dose in rat
  • Single raising dose in mouse
  • Single raising dose in dog
  • CYP Induction
  • Tissue distribution studies
  • MTD studies in rat and mouse
  • Mechanistic PK studies (Biliary excretion, First pass
    metabolism, BAL study)
  • Metabolic Characterization and Identification of In vivo
    samples
IND PACKAGE
  • Bioanalytical method validation in rodent and non-rodents
  • Single and multiple dose pharmacokinetics
  • Dose proportionality and absolute bioavailability in
    mouse, rat, and dog
  • Plasma protein binding in mouse, rat, dog, and human
    plasma
  • In vitro CYP450 inhibition (1A2, 2B6, 2C8, 2C9, 2C19, 2D6,
    3A4/5) in human liver microsomes
  • CYP induction in human hepatocytes
  • In vitro metabolism in, mouse, dog, and human hepatic
    preparations
  • Reaction phenotyping in recombinant CYPs or UGTs or other enzyme systems
  • Mini Ames
  • Contribution of P-glycoprotein (P-gp) and breast cancer
    resistant protein (BCRP) in limiting drug absorption or flux